Trade

with

Celsion Corp
(NASDAQ: CLSN)
AdChoices
2.55
-0.06
-2.30%
After Hours :
2.54
-0.01
-0.39%

Open

2.65

Previous Close

2.61

Volume (Avg)

91.90k (104.84k)

Day's Range

2.51-2.68

52Wk Range

2.38-5.90

Market Cap.

50.89M

Dividend Rate ( Yield )

-

Beta

1.76

Shares Outstanding

19.96M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 500.00k

    • Net Income

    • -8.25M

    • Market Cap.

    • 50.89M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -4,023.48

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.76

    • Forward P/E

    • -1.60

    • Price/Sales

    • 84.75

    • Price/Book Value

    • 1.12

    • Price/Cash flow

    • -2.81

      • EBITDA

      • -6.99M

      • Return on Capital %

      • -30.81

      • Return on Equity %

      • -51.35

      • Return on Assets %

      • -30.81

      • Book Value/Share

      • 2.27

      • Shares Outstanding

      • 19.96M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 8.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -1.59

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -27.52

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -4,023.48

            • 39.38

            • Net Profit Margin

            • -4,023.48

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.17

              • 0.76

              • Current Ratio

              • 6.51

              • 2.92

              • Quick Ratio

              • 6.51

              • 2.35

              • Interest Coverage

              • -18.12

              • 38.02

              • Leverage Ratio

              • 1.75

              • 2.21

              • Book Value/Share

              • 2.27

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.11

                • 188.68

                • P/E Ratio 5-Year High

                • -35.06

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.96

                • 124.82

                • Price/Sales Ratio

                • 84.75

                • 8.72

                • Price/Book Value

                • 1.12

                • 7.95

                • Price/Cash Flow Ratio

                • -2.81

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -51.35

                    (-240.90)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -30.81

                    (-111.20)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -41.11

                    (-225.60)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.01

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -15.41M
                  Operating Margin
                  -3,082.30
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -2.81
                  Ownership

                  Institutional Ownership

                  33.17%

                  Top 10 Institutions

                  34.84%

                  Mutual Fund Ownership

                  4.81%

                  Float

                  98.54%

                  5% / Insider Ownership

                  34.43%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Extended Market Index Fund

                  •  

                    269,349

                  • 0.00

                  • 1.35

                  • Vanguard Total Stock Mkt Idx

                  •  

                    214,403

                  • 0.00

                  • 1.07

                  • Perritt Ultra MicroCap Fund

                  •  

                    142,100

                  • 0.00

                  • 0.71

                  • Royce Micro-Cap Trust

                  •  

                    115,555

                  • 0.00

                  • 0.58

                  • iShares Micro-Cap

                  •  

                    44,803

                  • 0.00

                  • 0.19

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    37,190

                  • 0.00

                  • 0.19

                  • EB DL Non-SL Market Completion Fund

                  •  

                    25,193

                  • 1,728.23

                  • 0.13

                  • Vanguard Instl Total Stock Market Index

                  •  

                    21,241

                  • 0.00

                  • 0.11

                  • DFA U.S. Micro Cap Portfolio

                  •  

                    18,314

                  • 0.00

                  • 0.09

                  • Fidelity Spartan® Total Market Idx Fund

                  •  

                    10,682

                  • 0.00

                  • 0.05

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • BlackRock Fund Advisors

                  •  

                    901,529

                  • +4.42%

                  • 4.52

                  • Vanguard Group, Inc.

                  •  

                    535,075

                  • 0.00%

                  • 2.68

                  • Royce & Associates, LLC

                  •  

                    233,159

                  • 0.00%

                  • 1.17

                  • Susquehanna Financial Group, LLLP

                  •  

                    194,199

                  • +40.61%

                  • 0.97

                  • Sabby Management LLC

                  •  

                    150,047

                  • -33.95%

                  • 0.75

                  • D. E. Shaw & Co LP

                  •  

                    145,209

                  • -2.19%

                  • 0.73

                  • Perritt Capital Management Inc.

                  •  

                    142,100

                  • 0.00%

                  • 0.71

                  • Healthcare Value Capital LLC

                  •  

                    100,000

                  • -33.33%

                  • 0.50

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Growth

                  Celsion Corp was founded in 1982 and is a Delaware corporation. It is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. The Company is working t...moreo develop and commercialize chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. The Company’s product ThermoDox(r) is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer. ThermoDox(r) is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of various cancers. Localized heat at mild hyperthermia temperatures (g...morereater than 40 degrees Celsius) releases the encapsulated doxorubicin from the liposome enabling high concentrations of doxorubicin to be deposited preferentially in and around the targeted tumor. The Company is engaged in a limited amount of research and development in its own facilities and also sponsor research programs in partnership with various research institutions, including the National Cancer Institute and Duke University. Competition in the discovery and development of new methods for treating and preventing disease is intense. The Company face, and will continue to face, intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The Company is subject to the periodic inspection of its clinical trials, facilities, procedures and operations and/or the testing of its products by the FDA to determine whether its systems and processes are in compliance with FDA regulations. The Company’s research and development activities, pre-clinical tests and clinical trials, and ultimately the manufacturing, marketing and labeling of its products, are all subject to extensive regulation by the FDA and foreign regulatory agencies.lessless

                  Key People

                  Michael H. Tardugno

                  CEO/Director/President

                  Dr. Max E. Link,PhD

                  Chairman of the Board/Director

                  Mr. Jeffrey W. Church

                  CFO/Secretary/Senior VP, Divisional/Vice President

                  Dr. Khursheed Anwer, M.B.A.,PhD

                  Executive VP/Other Executive Officer

                  Dr. Nicholas Borys,M.D.

                  Chief Medical Officer/Vice President

                  • Celsion Corp

                  • 997 Lenox Drive

                  • Lawrenceville, NJ 08648

                  • USA.Map

                  • Phone: +1 609 896-9100

                  • Fax: +1 609 896-2200

                  • celsion.com

                  Incorporated

                  1982

                  Employees

                  13

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: